We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Atossa Therapeutics Inc | NASDAQ:ATOS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.14 | 9.21% | 1.66 | 1.60 | 1.70 | 1.70 | 1.53 | 1.53 | 1,360,532 | 05:00:06 |
Delaware
|
001-35610
|
26-4753208
|
||
(State or other jurisdiction of
incorporation) |
(Commission File Number)
|
(I.R.S. Employer
Identification No.) |
107 Spring Street
Seattle, Washington
|
98104
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Title of each class
|
Trading symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.18 par value
|
ATOS
|
The Nasdaq Capital Market
|
Exhibit No.
|
Description
|
|
104
|
Cover page Interactive Data File (embedded within the Inline XBRL document)
|
Date: November 7, 2022
|
Atossa Therapeutics, Inc.
|
|||
By:
|
/s/ Kyle Guse
|
|||
Kyle Guse
|
||||
Chief Financial Officer, General Counsel and Secretary
|
1 Year Atossa Therapeutics Chart |
1 Month Atossa Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions